Here is what the page “Moderna-Merck Cancer Vaccine Data Reveal: Key Numbers, Trial Details, and What to Expect” contains. Moderna and Merck are set to unveil new data on their personalized mRNA cancer vaccine, mRNA-4157 (V940), in combination with Merck's Keytruda, for high-risk melanoma patients. The upcoming reveal, expected at a major medical meeting, will provide updated results from the Phase 2b KEYNOTE-942 trial, which previously showed a 44% reduction in the risk of recurrence or death compared to Keytruda alone.
Investors and oncologists are closely watching for durability of response, overall survival trends, and biomarker data that could support a Phase 3 program and potential regulatory filings. Moderna's mRNA platform, proven in COVID-19 vaccines, is now being tested in cancer, with the companies already planning a Phase 3 trial in adjuvant melanoma and expansion into other tumor types. For the complete material, the listing points back to the source inside the network.